Spots Global Cancer Trial Database for hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
Official Title: Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study
Study ID: NCT03824691
Conditions
Study Description
Brief Summary: Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study
Detailed Description: an open-label, single-centre, phase 2,
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione IRCCS Istituto Nazionale Tumori, Milano, , Italy
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
